Health-Related Quality of Life (HRQL) in Cutaneous T-Cell Lymphoma: A Post Hoc Analysis Examining Disease Burden and Patient Characteristics from the Phase 3 Mavoric Trial in Mycosis Fungoides and Sézary Syndrome
Michi M. ShinoharaYoun H. KimKevin MolloyPietro QuaglinoJulia ScarisbrickSusan ThorntonKerry SandilandsJ. LiuAnnabel NixonAngela WilliamsPablo L. Ortiz‐Romero
0
Citation
0
Reference
10
Related Paper
Keywords:
Cutaneous T-cell lymphoma
Post-hoc analysis
Brentuximab vedotin
Cutaneous T-cell lymphoma
Peripheral T-cell lymphoma
Cutaneous lymphoma
Cite
Citations (23)
Mycosis fungoides (MF) is the most common subtype of Cutaneous T-Cell Lymphoma (CTCL). Patients with Skin of Color (SOC) may be disproportionately impacted by MF due to delayed diagnoses, limited research, and treatment differences. In this graphical review, we provide an overview of MF immunopathogenesis and demonstrate how it manifests differently in SOC patients. We also provide our hypothesis for why the disease process can result in a myriad of clinical presentations in SOC patients. Last, we provide a summary of current treatment options, highlighting ongoing clinical trials and opportunities to include SOC patients to promote health equity.
Cutaneous T-cell lymphoma
Peripheral T-cell lymphoma
Cite
Citations (2)
Among 63 patients with cutaneous T-cell lymphoma (CTCL), 29% (n = 18) had positive computed tomographic (CT) findings, with frequencies of 65% (n = 13) among patients thought to have stages II-IV disease at clinical examination and 12% (n = 5) among patients thought to have stage I. Among eight patients with atypical CTCL variants such as cutaneous large-cell lymphoma, only one had negative findings at CT; extracutaneous disease was not suspected in five before they underwent CT. In contrast, CT findings were positive in only 5% (n = 2) of patients with classic early mycosis fungoides-type CTCL (scaling patches, small epidermotropic CD4+ cells), and CT is unlikely to provide substantial information in this patient subgroup. Contrary to earlier reports, the authors' data suggest that body CT is extremely useful in staging and evaluating patients with CTCL. CT should be included in the evaluation of atypical CTCL variants, Sézary syndrome, advanced-stage mycosis fungoides, and cases in which the CTCL subtype is unclear.
Cutaneous T-cell lymphoma
Peripheral T-cell lymphoma
Cite
Citations (32)
Cutaneous T-cell lymphoma
Cite
Citations (0)
In theMARCH1995 issue of theArchives, Burg and Dummer,1in an Editorial, advanced the thesis that "small plaque (digitate) parapsoriasis is an 'abortive' cutaneous T-cell lymphoma and is not mycosis fungoides." Their conclusion is illogical; if small plaque parapsoriasis is a cutaneous T-cell lymphoma, even an "abortive" one (according toThe Oxford English Dictionary, abortivemeans unsuccessful), it is a lymphoma, and the T-cell lymphoma in skin characterized by scaly patches is mycosis fungoides. The concept of mycosis fungoides on which Burg and Dummer predicated their thinking is the conventional one set forth by Alibert in 1806,2which was restated by the coauthors in these words: "Mycosis fungoides is a nosologic defined entity that progressively develops through stages reflected in changes of the clinical as well as histologic features...." But the notion of mycosis fungoides as a disease that develops progressively is at variance
Cutaneous T-cell lymphoma
Peripheral T-cell lymphoma
Cutaneous lymphoma
T-Cell Lymphoma
Cite
Citations (68)
Cutaneous T-cell lymphoma
Peripheral T-cell lymphoma
T-Cell Lymphoma
Cite
Citations (9)
Cutaneous T-cell lymphoma
Cutaneous lymphoma
Cite
Citations (0)
Cutaneous T-cell lymphoma
Ablative case
Cite
Citations (60)
Cutaneous T-cell lymphoma
Peripheral T-cell lymphoma
Cutaneous lymphoma
Cite
Citations (16)
Abstract The practice of pre‐emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T‐cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome, highlighting the most promising molecules in different compartments. Further, we emphasize the need for continued multicentre efforts to validate available and new biomarkers and to develop prospective combinatorial panels of already discovered molecules.
Cutaneous T-cell lymphoma
Cutaneous lymphoma
Cite
Citations (30)